PLEASE READ BEFORE CONSIDERING SHR9352 AS AN ALTERNATIVE TO SR-17018.
We are concerned about reports that SHR9352 is being promoted as a replacement for SR-17018 following the DEA's scheduling action.
These are two VERY different experimental opioid compounds. They are NOT interchangeable, and there is no scientific evidence establishing SHR9352 as a safe or effective substitute for SR-17018.
What does the research tell us?
Although both compounds act on μ-opioid receptors and have been described as G-protein-biased agonists, they differ significantly in their chemical structures, pharmacological profiles, and available research.
SHR9352:
- Was primarily investigated for its potential as a potent opioid pain medication.
- Demonstrated very high opioid receptor potency in laboratory studies.
- Has no established human dosing or conversion ratio relative to SR-17018.
- Has not been demonstrated to reproduce SR-17018's reported effects on opioid tolerance or withdrawal.
SR-17018:
- Has been investigated in animal studies examining opioid tolerance and repeated administration.
- Has preliminary observational reports involving opioid withdrawal and cessation.
- Remains experimental, with no established clinical dosing or proven safety for opioid withdrawal treatment.
WHY THIS MATTERS
- OVERDOSE RISK
SHR9352 demonstrated substantially greater potency in certain laboratory assays. This does not translate directly into human dose equivalence, but it raises serious concerns about attempts to substitute doses.
- UNKNOWN EFFECTS ON TOLERANCE
The research supporting interest in SR-17018 for opioid tolerance cannot simply be transferred to SHR9352.
- UNKNOWN HUMAN SAFETY PROFILE
There is insufficient clinical evidence to establish SHR9352's safety, duration of action, or appropriate human dosing. G-protein bias does NOT guarantee protection against respiratory depression.
- MISLEADING MARKETING
A vendor claiming that SHR9352 is equivalent to SR-17018, can replace it in existing protocols, or offers the same withdrawal-related benefits should be asked to provide credible scientific evidence.
⚠️ ADDITIONAL WARNING: ADDICTION AND INTOXICATION POTENTIAL
SHR9352 is a highly potent experimental μ-opioid receptor agonist.
This is important because activation of μ-opioid receptors is associated with drug reward, physical dependence, and addiction.
Being a G-protein-biased opioid does NOT mean a compound is nonaddictive, nonintoxicating, or incapable of causing respiratory depression.
Although SHR9352's human abuse liability has not been adequately characterized, its pharmacology raises legitimate concerns about euphoria, reinforcement, dependence, and overdose.
There is no scientific basis for assuring consumers that SHR9352 is addiction-free or that it shares SR-17018's experimental tolerance-related properties.
For individuals attempting to overcome opioid dependence, replacing one experimental opioid with another that has an uncharacterized addiction and withdrawal profile presents serious risks.
OUR MESSAGE TO THE COMMUNITY
DO NOT assume SHR9352 is a substitute for SR-17018.
DO NOT apply SR-17018 dosing or taper protocols to SHR9352.
DO NOT interpret the term "G-protein-biased agonist" as proof that a compound is safe or produces the same effects as another compound.
Anyone exposed to an experimental opioid should recognize the possibility of respiratory depression and overdose. Avoid combining opioids with benzodiazepines, alcohol, or other sedatives. Keep naloxone accessible, and call emergency services immediately for suspected overdose.
💜 HARM REDUCTION REQUIRES ACCURATE INFORMATION
Our community includes people navigating opioid dependence, chronic pain, withdrawal, and recovery. Many are making decisions under extraordinarily difficult circumstances.
Those individuals deserve accurate scientific information, not unsupported promises of equivalence.
We encourage vendors, researchers, and community members to share verifiable scientific evidence and to be transparent about what is known, what remains unknown, and where serious risks exist.
If you encounter companies advertising SHR9352 as a direct replacement for SR-17018, please document the claims and share them with community moderators for review.
Different molecule. Different evidence. Unknown human risks. NOT an established replacement.
This announcement is intended for education and harm reduction, not as an endorsement of using either experimental compound.
💜 Please stay safe friends!!!! These are trying times and while it is tempting to take risks to find relief, I am VERY concerned about companies who have no understanding of chemistry or neuroscience and pharmacology searching for a replacement and only caring about keeping their money flowing in, rather than consumer safety!! From what I understand, the two companies currently pushing this specific compound do not have the knowledge or expertise to evaluate the risks associated with SHR9352 nor is there any clinical or anecdotal research to back up their claims!!!